Taiwan S.E.
2025-01-22
5-day change
1st Jan Change
69.00 TWD
-0.43%
+5.99%
+5.83%
Tanvex BioPharma, Inc.(TWSE:6541) added to Taiwan TAIEX Index
Tanvex BioPharma, Inc.Taiwan TAIEX Index
Tanvex BioPharma USA, Inc. announced that it expects to receive $50 million in funding from Tanvex BioPharma, Inc.
01-20
CI
Tanvex BioPharma, Inc. completed the acquisition of Bora Biologics Co., Ltd. from Bora Pharmaceuticals Co., LTD. and others for TWD 4.52 billion.
01-19
CI
Tanvex BioPharma-Bora Biologics Merger to Occur on Jan. 20
01-09
MT
Tanvex BioPharma Fails to Secure FDA Nod for Cancer Drug Approval
01-06
MT
Tanvex BioPharma Revises 2023 Cash Capital Increase Fund Allocation
12-19
MT
Tanvex BioPharma, Inc.(TWSE:6541) added to Taiwan TAIEX Index
12-05
CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
11-12
CI
Tanvex BioPharma Names CFO
11-11
MT
Tanvex BioPharma, Inc. Appoints Angela Luan as Corporate Governance Officer, Effective November 11, 2024
11-08
CI
Tanvex BioPharma, Inc. Appoints Angela Luan as Chief Financial Officer, Effective November 11, 2024
11-08
CI
Shareholders OK Tanvex BioPharma-Bora Biologics Merger
24-10-16
MT
Tanvex BioPharma, Inc. Announces Change of CEO
24-09-04
CI
Bora Pharmaceuticals to Merge Unit with Tanvex BioPharma
24-08-28
MT
Tanvex BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
24-08-28
CI
Tanvex BioPharma, Inc. announced that it expects to receive funding from Bora Pharmaceuticals Co., LTD.
24-08-26
CI
Tanvex BioPharma, Inc. agreed to acquire Bora Biologics Co., Ltd. from Bora Pharmaceuticals Co., LTD. and others for TWD 4.52 billion.
24-08-26
CI
Tanvex BioPharma, Inc. Announces CFO Changes, Effective June 30, 2024
24-06-28
CI
Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024
24-06-19
CI
Tanvex BioPharma, Inc. Announces Change of Audit Committee Members
24-06-19
CI
Tanvex BioPharma, Inc. Announces Change of Remuneration Committee Members
24-06-19
CI
Tanvex BioPharma, Inc. Announces Board Changes
24-06-19
CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from Taiwan TAIEX Index
24-06-13
CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index
24-05-27
CI
Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
24-05-12
CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
24-03-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
6541: Dynamic Chart
Tanvex BioPharma, Inc. is a Cayman Islands-based contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company. The Company specializes in research, product development, manufacture, and commercialization of biologic and biosimilar drugs. It has expertise in all areas, such as strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and warehousing, sales and distribution. The Company's CDMO services operate under the name Bora Biologics. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. It deploys a range of Current Good Manufacturing Practice (cGMP) biologics manufacturing capabilities.
More about the company
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
